Serplulimab Achieves 42.5% pCR Rate in Neoadjuvant Colon Cancer
The 2026 European Society for Radiotherapy and Oncology (ESTRO 2026) was held in Stockholm, Sweden, from May 15 to 19 local time. At this conference, Henlius’ innovative anti-PD-1 monoclonal antibody(mAb) serplulimab was officially presented in an oral report for its neoadjuvant therapy study results in locally advanced high-risk colon cancer (LACC). The study was jointly initiated by Professor Sanjun Cai and Professor Zhen Zhang of Fudan University Shanghai Cancer Center. The results showed that radiochemotherapy combined with serplulimab demonstrated favorable efficacy, with the pathological complete response (pCR) rate significantly increased to 42.5%, representing more than a four-fold improvement over the control group. This offers a new treatment option for high-risk LACC and further validates the therapeutic value of serplulimab in the field of gastrointestinal cancers.
Share:
More News
Taiho Oncology, Inc. completed a New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) for zipalertinib in combination with platinum-based chemotherapy for the treatment of patients with previously untreated, locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20
“This collaboration reflects our conviction that atebimetinib has the potential to become an essential backbone therapy in a broad range of combinations across MAPK-driven cancers,” said Ben Zeskind, Immuneering CEO and co-founder. “Atebimetinib’s unique tolerability profile and broad activity make it well suited to combine with a wide range of
“These final updated results provide continued evidence of the potential for γδ T cell therapies to drive activity and improve outcomes for patients,” said William Ho, CEO and co-founder of IN8bio. “The clinical outcomes and observed activity are supported by our correlative analysis, including histopathology, demonstrating the expansion and persistence
“Patients with RAS-mutated mCRC have no first-line therapies specifically approved for their disease, and Fast Track designation reflects the potential of onvansertib to address this serious unmet need,” said Mani Mohindru, PhD, President and Chief Executive Officer of Cardiff Oncology. “Our randomized Phase 2 data give us confidence that onvansertib